Cluster features in fibrosing interstitial lung disease and associations with prognosis

被引:0
作者
Wang, Yuanying [1 ]
Sun, Di [1 ]
Wang, Jingwei [1 ]
Yu, Shiwen [1 ,2 ]
Wu, Na [1 ,2 ]
Ye, Qiao [1 ,2 ]
机构
[1] Capital Med Univ, Affiliated Beijing Chao Yang Hosp, Beijing Inst Resp Med, Clin Ctr Interstitial Lung Dis, Beijing, Peoples R China
[2] Capital Med Univ, Affiliated Beijing Chao Yang Hosp, Dept Occupat Med & Toxicol, Beijing, Peoples R China
关键词
Pulmonary fibrosis; Interstitial lung diseases; Cluster analysis; Prognosis; Acute exacerbation; IDIOPATHIC PULMONARY-FIBROSIS; ACUTE EXACERBATION; DOUBLE-BLIND; IDENTIFICATION; PIRFENIDONE; DIAGNOSIS; UPDATE;
D O I
10.1186/s12890-023-02735-7
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Clustering is helpful in identifying subtypes in complex fibrosing interstitial lung disease (F-ILD) and associating them with prognosis at an early stage of the disease to improve treatment management. We aimed to identify associations between clinical characteristics and outcomes in patients with F-ILD.Methods Retrospectively, 575 out of 926 patients with F-ILD were eligible for analysis. Four clusters were identified based on baseline data using cluster analysis. The clinical characteristics and outcomes were compared among the groups.Results Cluster 1 was characterized by a high prevalence of comorbidities and hypoxemia at rest, with the worst lung function at baseline; Cluster 2 by young female patients with less or no smoking history; Cluster 3 by male patients with highest smoking history, the most noticeable signs of velcro crackles and clubbing of fingers, and the severe lung involvement on chest image; Cluster 4 by male patients with a high percentage of occupational or environmental exposure. Clusters 1 (median overall survival [OS] = 7.0 years) and 3 (OS = 5.9 years) had shorter OS than Clusters 2 (OS = not reached, Cluster 1: p < 0.001, Cluster 3: p < 0.001) and 4 (OS = not reached, Cluster 1: p = 0.004, Cluster 3: p < 0.001). Clusters 1 and 3 had a higher cumulative incidence of acute exacerbation than Clusters 2 (Cluster 1: p < 0.001, Cluster 3: p = 0.014) and 4 (Cluster 1: p < 0.001, Cluster 3: p = 0.006). Stratification by using clusters also independently predicted acute exacerbation (p < 0.001) and overall survival (p < 0.001).Conclusions The high degree of disease heterogeneity of F-ILD can be underscored by four clusters based on clinical characteristics, which may be helpful in predicting the risk of fibrosis progression, acute exacerbation and overall survival.
引用
收藏
页数:11
相关论文
共 34 条
  • [1] Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort
    Adegunsoye, Ayodeji
    Oldham, Justin M.
    Chung, Jonathan H.
    Montner, Steven M.
    Lee, Cathryn
    Witt, Leah J.
    Stahlbaum, Danielle
    Bermea, Rene S.
    Chen, Lena W.
    Hsu, Scully
    Husain, Aliya N.
    Noth, Imre
    Vij, Rekha
    Strek, Mary E.
    Churpek, Matthew
    [J]. CHEST, 2018, 153 (02) : 349 - 360
  • [2] Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
    Aimo, Alberto
    Spitaleri, Giosafat
    Nieri, Dario
    Tavanti, Laura Maria
    Meschi, Claudia
    Panichella, Giorgia
    Lupon, Josep
    Pistelli, Francesco
    Carrozzi, Laura
    Bayes-Genis, Antoni
    Emdin, Michele
    [J]. CARDIAC FAILURE REVIEW, 2022, 8
  • [3] American Thoracic S., 2002, AM J RESP CRIT CARE, V165, P277, DOI [10.1164/ajrccm.165.2.ats01, 10.1164/rccm.2009-040GL, DOI 10.1164/RCCM.2009-040GL, DOI 10.1164/AJRCCM.165.2.ATS01]
  • [4] Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis
    Badagliacca, Roberto
    Rischard, Franz
    Papa, Silvia
    Kubba, Saad
    Vanderpool, Rebecca
    Yuan, Jason X-J
    Garcia, Joe G. N.
    Airhart, Sophia
    Poscia, Roberto
    Pezzuto, Beatrice
    Manzi, Giovanna
    Miotti, Cristiano
    Luongo, Federico
    Scoccia, Gianmarco
    Sciomer, Susanna
    Torre, Roberto
    Fedele, Francesco
    Vizza, Carmine Dario
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04) : 310 - 320
  • [5] Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
    Behr, Juergen
    Prasse, Antje
    Kreuter, Michael
    Johow, Johannes
    Rabe, Klaus F.
    Bonella, Francesco
    Bonnet, Reiner
    Grohe, Christian
    Held, Matthias
    Wilkens, Heinrike
    Hammerl, Peter
    Koschel, Dirk
    Blaas, Stefan
    Wirtz, Hubert
    Ficker, Joachim H.
    Neumeister, Wolfgang
    Schoenfeld, Nicolas
    Claussen, Martin
    Kneidinger, Nikolaus
    Frankenberger, Marion
    Hummler, Simone
    Kahn, Nicolas
    Tello, Silke
    Freise, Julia
    Welte, Tobias
    Neuser, Petra
    Guenther, Andreas
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (05) : 476 - 486
  • [6] Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report
    Collard, Harold R.
    Ryerson, Christopher J.
    Corte, Tamera J.
    Jenkins, Gisli
    Kondoh, Yasuhiro
    Lederer, David J.
    Lee, Joyce S.
    Maher, Toby M.
    Wells, Athol U.
    Antoniou, Katerina M.
    Behr, Juergen
    Brown, Kevin K.
    Cottin, Vincent
    Flaherty, Kevin R.
    Fukuoka, Junya
    Hansell, David M.
    Johkoh, Takeshi
    Kaminski, Naftali
    Kim, Dong Soon
    Kolb, Martin
    Lynch, David A.
    Myers, Jeffrey L.
    Raghu, Ganesh
    Richeldi, Luca
    Taniguchi, Hiroyuki
    Martinez, Fernando J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (03) : 265 - 275
  • [7] Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
    Collins, Bridget F.
    Raghu, Ganesh
    [J]. EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153)
  • [8] Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases
    Cottin, Vincent
    Hirani, Nikhil A.
    Hotchkin, David L.
    Nambiar, Anoop M.
    Ogura, Takashi
    Otaola, Maria
    Skowasch, Dirk
    Park, Jong Sun
    Poonyagariyagorn, Hataya K.
    Wuyts, Wim
    Wells, Athol U.
    [J]. EUROPEAN RESPIRATORY REVIEW, 2018, 27 (150)
  • [9] Statistical power for cluster analysis
    Dalmaijer, Edwin S.
    Nord, Camilla L.
    Astle, Duncan E.
    [J]. BMC BIOINFORMATICS, 2022, 23 (01)
  • [10] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Walsh, S. L. F.
    Inoue, Y.
    Richeldi, L.
    Kolb, M.
    Tetzlaff, K.
    Stowasser, S.
    Coeck, C.
    Clerisme-Beaty, E.
    Rosenstock, B.
    Quaresma, M.
    Haeufel, T.
    Goeldner, R-G
    Schlenker-Herceg, R.
    Brown, K. K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18) : 1718 - 1727